You are here

  • Home
  • Archive
  • Volume 9, Issue 10
  • Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial

 

Online download statistics by month:

Online download statistics by month: October 2021 to September 2025

AbstractFullPdf
Oct 2021423424136
Nov 202117717764
Dec 202112612637
Jan 202210210761
Feb 2022585846
Mar 2022505070
Apr 2022555833
May 2022556231
Jun 2022849137
Jul 2022718128
Aug 2022596020
Sep 2022585829
Oct 2022505736
Nov 2022404020
Dec 2022333313
Jan 2023293127
Feb 2023565718
Mar 202318197
Apr 2023202018
May 2023272729
Jun 202318188
Jul 2023181818
Aug 2023111113
Sep 2023161620
Oct 2023161613
Nov 2023222212
Dec 2023282813
Jan 2024343515
Feb 2024373825
Mar 2024191943
Apr 2024434338
May 2024242514
Jun 2024424128
Jul 2024485029
Aug 2024242222
Sep 2024262630
Oct 2024343420
Nov 2024353621
Dec 2024404116
Jan 2025383821
Feb 2025555539
Mar 2025585832
Apr 2025565736
May 2025353549
Jun 2025272741
Jul 2025110
Sep 2025220
Total239824481376